Virginie Buggia-Prevot, PhD

Virginie Buggia-Prevot is a drug discovery scientist with 20+ years of expertise in Parkinson’s and Alzheimer’s diseases. She leads Neurology Discovery and Target Portfolio Strategy across therapeutic areas at Valo Health, a technology company leveraging human data and artificial intelligence-driven computation to drive small molecule therapeutic development. Her team has developed novel computational approaches to discover targets for neurodegenerative diseases, including Parkinson’s disease, that provide insights on a target’s association to disease outcomes, directionality for intervention, and cell type specificity. Prior to Valo, Virginie led the novel target discovery and validation group at the Belfer Neurodegeneration Consortium at MD Anderson whose mission is to collaborate with academic leaders and translate knowledge into therapeutic interventions for neurodegenerative diseases. She was a major contributor on a neuroprotective small molecule program that led to the launch of Magnolia Neurosciences and was awarded a grant from MJFF to evaluate its potential in Parkinson’s disease.